We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.90 | 2.56% | 36.00 | 35.50 | 36.50 | 36.50 | 35.25 | 35.25 | 480,551 | 11:53:39 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 27.17M | -26.94M | -0.0746 | -4.83 | 130.05M |
From Apr 2019 to Apr 2024
TIDMCREO
RNS Number : 4703X
Creo Medical Group PLC
24 November 2017
Creo Medical Group plc
("Creo" or "the Company")
Annual Reports and Accounts and Notice of Annual General Meeting
Chepstow, South Wales - 24 November 2017 - Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, today announces that its Annual Report and Accounts for the year ended 30 June 2017 together with its Notice of Annual General Meeting (AGM) have been sent to shareholders. These documents are available on the Company's website: http://investors.creomedical.com.
The AGM will be held at 10 am on Wednesday 20 December 2017 at the Company's registered office, Block B, Beaufort Park, Chepstow, Wales NP16 5TY.
Hot Features
Premium
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume/Mark Brett Pollard
+44 (0)129 160 Connelly (NOMAD) / Mo Noonan
6005 richard.rees@creomedical.com Michael Johnson / +44 (0)203 727
Russell Kerr (Sales) 1000
+44 (0)207 397 8900 creo@fticonsulting.com
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAUSSRRBBAAUAA
(END) Dow Jones Newswires
November 24, 2017 05:49 ET (10:49 GMT)
1 Year Creo Medical Chart |
1 Month Creo Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
